Clinical services
Clinical update
On January 30, 2025, Axsome Therapeutics announced the U.S. FDA approval of Symbravo for the acute treatment of migrane.
White paper
Climate change poses significant health risks for workers. Optum programs work together to address an injured worker’s varied and often codependent needs.
White paper
GLP-1 medications can offer substantial benefits for overweight injured workers. Our clinical and policy experts can help you navigate the evolving GLP-1 landscape.
Article
Formulary management works with the authorization process to support worker safety, reduce complexity, and prevent unintended billing errors.
Clinical update
On January 30, 2025, the U.S. FDA approved Journavx™ (suzetrigine) for the treatment of moderate-to-severe acute pain in adults.
Article
Exploring an injured worker’s health story builds trust and helps pharmacists offer more compassionate and informed care.